179 related articles for article (PubMed ID: 27300551)
1. Treatment-Related Death during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Studies.
Zhao J; Xia Y; Kaminski J; Hao Z; Mott F; Campbell J; Sadek R; Kong FM
PLoS One; 2016; 11(6):e0157455. PubMed ID: 27300551
[TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
[TBL] [Abstract][Full Text] [Related]
3. The effect of induction chemotherapy in patients with locally advanced nonsmall cell lung cancer who received chemoradiotherapy: A systematic review and meta-analysis.
Luo H; Yu X; Liang N; Xie J; Deng G; Liu Q; Zhang J; Zhang J; Ge H
Medicine (Baltimore); 2017 Feb; 96(8):e6165. PubMed ID: 28225501
[TBL] [Abstract][Full Text] [Related]
4. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
5. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer.
Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A
Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
Salama JK; Stinchcombe TE; Gu L; Wang X; Morano K; Bogart JA; Crawford JC; Socinski MA; Blackstock AW; Vokes EE;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e269-74. PubMed ID: 21477940
[TBL] [Abstract][Full Text] [Related]
7. [Concurrent chemoradiotherapy followed by consolidation chemotherapy and sequential chemoradiotherapy for stage III non-small cell lung cancer: comparison in 93 patients].
Sun WZ; Song LP; Zhang YB; Ai T; Lu JL; Ren J; Gao Y
Nan Fang Yi Ke Da Xue Xue Bao; 2012 Mar; 32(3):362-7. PubMed ID: 22445984
[TBL] [Abstract][Full Text] [Related]
8. S-1-based concurrent chemoradiotherapy in the treatment of locally advanced non-small cell lung cancer: A systematic review and meta-analysis protocol.
Liu F; Wang C; Hu T; Wang W
Medicine (Baltimore); 2018 Apr; 97(15):e0397. PubMed ID: 29642202
[TBL] [Abstract][Full Text] [Related]
9. Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis.
Yuan M; Zhai Y; Men Y; Wang J; Deng L; Wang W; Bao Y; Yang X; Sun S; Ma Z; Liu Y; Wang J; Zhu H; Hui Z
Thorac Cancer; 2021 Dec; 12(23):3208-3215. PubMed ID: 34676669
[TBL] [Abstract][Full Text] [Related]
10. A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
Zheng Q; Min S; Zhou Y
BMC Cancer; 2022 Jun; 22(1):674. PubMed ID: 35725420
[TBL] [Abstract][Full Text] [Related]
11. Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study.
Takase N; Hattori Y; Kiriu T; Itoh S; Kawa Y; Yamamoto M; Urata Y; Shimada T; Tsujino K; Soejima T; Negoro S; Satouchi M
Respir Investig; 2016 Sep; 54(5):334-40. PubMed ID: 27566381
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.
Zhang SL; Han CB; Sun L; Huang LT; Ma JT
Radiat Oncol; 2020 Aug; 15(1):205. PubMed ID: 32831120
[TBL] [Abstract][Full Text] [Related]
13. [Outcome of concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer patients].
Liu L; Wang X; Ji Z; Wang J; Bi N; Hui Z; Lyu J; Liang J; Zhou Z; Feng Q; Chen D; Zhang H; Xiao Z; Yin W; Wang L
Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):863-7. PubMed ID: 26887520
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
Bi N; Liu L; Liang J; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang J; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Zhang T; Yin W; Li J; He J; Wang L
BMC Cancer; 2020 Apr; 20(1):278. PubMed ID: 32252680
[TBL] [Abstract][Full Text] [Related]
15. The impact of right ventricular function on prognosis in patients with stage III non-small cell lung cancer after concurrent chemoradiotherapy.
Chen L; Huang J; Wu W; Ta S; Xie X
Int J Cardiovasc Imaging; 2019 Jun; 35(6):1009-1017. PubMed ID: 30941563
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcome of Palliative Concurrent Chemoradiotherapy with Cisplatin/Docetaxel for Stage III Non-small Cell Lung Cancer.
Katsui K; Ogata T; Watanabe K; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S
Acta Med Okayama; 2021 Jun; 75(3):269-277. PubMed ID: 34176930
[TBL] [Abstract][Full Text] [Related]
17. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
[TBL] [Abstract][Full Text] [Related]
18. A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
Oh IJ; Kim KS; Kim YC; Ban HJ; Kwon YS; Kim YI; Lim SC; Chung WK; Nam TK; Song JY; Yoon MS; Ahn SJ
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1247-54. PubMed ID: 24091849
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Thymosin α1 in Management of Radiation Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiotherapy: A Phase 2 Clinical Trial (GASTO-1043).
Liu F; Qiu B; Xi Y; Luo Y; Luo Q; Wu Y; Chen N; Zhou R; Guo J; Wu Q; Xiong M; Liu H
Int J Radiat Oncol Biol Phys; 2022 Nov; 114(3):433-443. PubMed ID: 35870709
[TBL] [Abstract][Full Text] [Related]
20. Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Bi N; Liang J; Zhou Z; Chen D; Fu Z; Yang X; Feng Q; Hui Z; Xiao Z; Lv J; Wang X; Zhang T; Wang X; Deng L; Wang W; Wang J; Liu L; Hu C; Wang L
JAMA Netw Open; 2019 Dec; 2(12):e1918070. PubMed ID: 31851351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
